Patent Daily RSS
Twitter Guna
- Happy #gobackmodi day 1 year ago
- RT @nikhilkarani1: Aurobindo acquires oral solid & derm Biz of Sandoz - Acqd Biz has sales worth $1.2bn & Aurobindo wud pay $900mn in cash… 1 year ago
- RT @ainvvy: 0. On Independence day, I look briefly at how some of the current states came into being. Some of them I had not even heard be… 1 year ago
- RT @digvijaya_28: Political turmoil in TN and Governor playing truant. Is he fulfilling his duties ? No. He is doing politics under directi… 3 years ago
- RT @VikasDandekarET: #Cipla bets on speciality #pharma business in US; aims for commercial launches by 2020 economictimes.indiatimes.com/industry/healt… 4 years ago
- RT @scarthik: @itisprashanth வாழ்வில் நமதுதேவை குறித்த தெளிவான தேர்வும், அதைநோக்கிய நேர்மையான தேடலும்இருந்துவிட்டால், வெற்றி கூடிவரும். அமை… 4 years ago
Daily Archives: 20/01/2011
Patents & IP news: 20/01/2011
1) Biocon says revenue from Pfizer deal to begin in fiscal 2012 (Bloomberg); Pfizer and Biocon recently entered into agreement. Under this agreement, Pfizer will have exclusive rights to commercialise Biocon’s drugs recombinant human insulin, Glargine, Aspart and Lispro globally with certain … Continue reading
Posted in Daily interesting IP news
2 Comments
Novo nordisk – repaglinide combination patent invalid
Yesterday, The district court of Michigan ruled that OB listed 6,677,358 (exp: Jun 12, 2018) patent is invalid and unenforceable. Press release “… The district court ruled that the patent, which covers the combination use of repaglinide and metformin for the treatment of type 2 … Continue reading
Posted in Daily interesting IP news, Patent case
Tagged carco, metformin, novo nordisk, repaglinide, sun
Leave a comment
